Impact of Tocilizumab (Anti–IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection
Conclusions. TCZ reduced total IgG and IgG1-3 and anti–HLA-total IgG and IgG3 levels, suggesting that TCZ suppresses Ig production in B cells nonspecifically, likely through inhibition of interleukin 6–mediated signaling to B cells and plasma cells. This may be a contributing factor for the beneficial effect of TCZ on cAMR observed in this patient population. (Source: Transplantation)
Source: Transplantation - April 1, 2020 Category: Transplant Surgery Tags: Original Clinical Science—General Source Type: research
Cytomegalovirus Immune Globulin (CMV-Ig): An Old Drug with Fewer Tricks - Removal of Prophylactic CMV-Ig Administration in CMV Mismatched Lung Transplant Recipients
The routine use of cytomegalovirus immune globulin (CMV-Ig) to provide passive immunity to cytomegalovirus (CMV) in patients is not supported in published literature. International guidelines do not advocate for the use of CMV-Ig alone in thoracic transplant and provide only weak recommendations for its role in combination with antiviral therapy for prevention of CMV. The utilization of CMV-Ig incurs significant cost, and carries the potential for infusion related toxicities. Furthermore, in 2012, an international survey reported only 38 % of thoracic transplant centers utilized CMV-Ig as part of a universal prophylaxis pr...
Source: The Journal of Heart and Lung Transplantation - April 1, 2020 Category: Transplant Surgery Authors: B.J. Pierce, C. Pham, S. Varnado Balk, H. Huang Tags: (1300) Source Type: research
Comparison of Outcomes in Heart Transplant Recipients Receiving CMV Prophylaxis with CMV IVIG with Valganciclovir versus Valganciclovir Alone
Cytomegalovirus (CMV) remains one of the most common opportunistic infections affecting orthotopic heart transplant (OHT) patients, with seronegative (R-) recipients receiving transplants from seropositive donors (D+) being at the highest risk. CMV intravenous immune globulin (CMV IVIG) use for prophylaxis has been limited since the release of valganciclovir (VGC) due to efficacy, infusion-related toxicities, and cost. The ISHLT guidelines for the care of heart transplant recipients state there may be a role for CMV IVIG in high risk (D+/R-) OHT in combination with VCG, but it is not clearly defined. (Source: The Journal o...
Source: The Journal of Heart and Lung Transplantation - April 1, 2020 Category: Transplant Surgery Authors: I. Moss, A. Brueckner, A. Rumore Tags: (1225) Source Type: research
Management of Major Bleeds in Patients with Immune Thrombocytopenia.
Abstract BACKGROUND: A standard approach to the recognition and management of major bleeding in immune thrombocytopenia (ITP) is lacking. METHODS: Retrospective cohort study of ITP patients presenting to the ED with severe thrombocytopenia (platelet count
Source: Thrombosis and Haemostasis - March 26, 2020 Category: Hematology Authors: Mithoowani S, Cervi A, Shah N, Ejaz R, Sirotich E, Barty R, Li N, Nazy I, Arnold DM Tags: J Thromb Haemost Source Type: research
Plasma Cell Myeloma Type Posttransplant Lymphoproliferative Disorder in an 18-Month-Old Heart Transplant Recipient: Case Report and Review of the Literature
We present a case of Epstein-Barr virus positive monomorphic plasma cell myeloma type PTLD that developed 10 months after cardiac transplant in an 18-month-old boy. The bone marrow showed replacement by about 20% to 40% lambda-restricted plasmacytoid lymphocytes and plasma cells (by immunohistochemistry and flow cytometry, respectively). His serum free lambda to kappa light chain ratio was>300, comparable to that seen in myeloma in nontransplant patients. The neoplastic cells were Epstein-Barr virus small RNA positive by in situ hybridization. He was treated with rituximab in combination with ganciclovir, intravenous im...
Source: Journal of Pediatric Hematology Oncology - March 25, 2020 Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research
The anti –heat stress effects of Chinese herbal medicine prescriptions and rumen‐protected γ‐aminobutyric acid on growth performance, apparent nutrient digestibility, and health status in beef cattle
This study aims to evaluate the anti –heat stress effect of Chinese herbal medicine (CHM) prescription, rumen‐protected γ‐aminobutyric acid (RP‐GABA), and CHM plus RP‐GABA co‐medication on growth performance, apparent digestibility, and serum parameters in heat‐stressed beef cattle. Forty beef cattle were randomly divide d into four groups. Control group was supplied with basal diet, while CHM, γ‐aminobutyric acid (GABA), and CHM + GABA groups were, respectively, supplied with CHM, RP‐GABA, and CHM plus RP‐GABA in basal diet. Our result indicated that CHM + GABA eleva...
Source: Animal Science Journal - March 23, 2020 Category: Zoology Authors: Jian Chen, Kun Guo, Xiaozhen Song, Lvtao Lan, Shiqi Liu, Ruiming Hu, Junrong Luo Tags: ORIGINAL ARTICLE Source Type: research
Mean platelet volume and response to the first line therapy in newly diagnosed adult immune thrombocytopenia patients: A retrospective study.
CONCLUSION: MPV can be used as a predictor of early response to the first line treatment in newly diagnosed adult primary ITP patients. PMID: 32178511 [PubMed - as supplied by publisher] (Source: Turkish Journal of Medical Sciences)
Source: Turkish Journal of Medical Sciences - March 19, 2020 Category: General Medicine Tags: Turk J Med Sci Source Type: research
Clinical Practice Experience with HyQvia in Adults Using Alternative Dosing Regimens and Pediatric Patients: A Retrospective Study
ConclusionsA shorter ramp-up schedule did not appear to increase the number of AEs compared to standard ramp-up schedules. For patients with AEs, slower infusion rates and the use of two sites may improve medication tolerability. Four of five pediatric patients reported no AEs, and only one discontinued, stating a fear of needles. HyQvia may be tailored to adults requiring alternative rates, ramp-up, and/or dosing regimens and may be especially well-suited to children. (Source: Advances in Therapy)
Source: Advances in Therapy - March 2, 2020 Category: Drugs & Pharmacology Source Type: research
Letter to the Editor: Reply to "Safety and varicella outcomes after varicella zoster immune globulin administration in pregnancy"
(Source: American Journal of Obstetrics and Gynecology)
Source: American Journal of Obstetrics and Gynecology - February 20, 2020 Category: OBGYN Authors: Susanna Giach é, Michele Trotta, Beatrice Borchi, Lorenzo Zammarchi Tags: Letter to the Editors Source Type: research
Regarding “Safety and varicella outcomes after varicella zoster immune globulin administration in pregnancy”
In a recent issue of your journal, Swamy and Dotters-Katz summarized the results of a randomized controlled trial (RCT) and an expanded-access program (EAP) in which pregnant women exposed to varicella zoster virus (VZV) received varicella zoster immune globulin (VZIG) as postexposure prophylaxis.1 Varicella incidence was 29% and 7.3% in the RCT and EAP cohorts, respectively. These rates are significantly lower if compared with the 42% reported in our previously published 20 year retrospective study. (Source: American Journal of Obstetrics and Gynecology)
Source: American Journal of Obstetrics and Gynecology - February 20, 2020 Category: OBGYN Authors: Susanna Giach é, Michele Trotta, Beatrice Borchi, Lorenzo Zammarchi, Michele Trotta, Beatrice Borchi, Lorenzo Zammarchi Tags: Letter to the Editors Source Type: research
Immune globulin subcutaneous, human 20% solution (Xembify®), a new high concentration immunoglobulin product for subcutaneous administration
Publication date: Available online 19 February 2020Source: BiologicalsAuthor(s): William Alonso, Pete Vandeberg, John Lang, Jeffrey Yuziuk, Rebecca Silverstein, Kenya Stokes, Dennis McBride, Maria Cruz, Doug Burns, W. Keither Merritt, Todd Willis, Juan I. JorqueraAbstractImmune globulin subcutaneous, human 20% solution (IGSC-C 20%, Xembify®)—a new 20% immunoglobulin (IgG) liquid product for subcutaneous (SC) administration—has been developed by Grifols. The IGSC-C 20% formulation is based on knowledge acquired from the formulation of Immune Globulin Injection (Human),10% Caprylate/Chromatography Purified (I...
Source: Biologicals - February 19, 2020 Category: Biology Source Type: research
Immune globulin subcutaneous, human 20% solution (Xembify ®), a new high concentration immunoglobulin product for subcutaneous administration.
Immune globulin subcutaneous, human 20% solution (Xembify®), a new high concentration immunoglobulin product for subcutaneous administration. Biologicals. 2020 Feb 18;: Authors: Alonso W, Vandeberg P, Lang J, Yuziuk J, Silverstein R, Stokes K, McBride D, Cruz M, Burns D, Merritt WK, Willis T, Jorquera JI Abstract Immune globulin subcutaneous, human 20% solution (IGSC-C 20%, Xembify®)-a new 20% immunoglobulin (IgG) liquid product for subcutaneous (SC) administration-has been developed by Grifols. The IGSC-C 20% formulation is based on knowledge acquired from the formulation of Immune Globulin I...
Source: Biologicals : Journal of the International Association of Biological Standardization - February 18, 2020 Category: Biotechnology Authors: Alonso W, Vandeberg P, Lang J, Yuziuk J, Silverstein R, Stokes K, McBride D, Cruz M, Burns D, Merritt WK, Willis T, Jorquera JI Tags: Biologicals Source Type: research
Rhesus D factor (RhD) negative women ’s experiences with pregnancy: An interpretive description
The development of rh immune globulin (RhIG) for the prevention of Rhesus D (RhD) alloimmunization has significantly decreased the incidence of RhD alloimmunization. Despite long-standing prevention, the experiences of RhD negative women with pregnancy is absent in the literature. (Source: Women and Birth)
Source: Women and Birth - February 5, 2020 Category: Midwifery Authors: Trina M. Fyfe, Jos ée G. Lavoie, Geoffrey W. Payne, Davina Banner Source Type: research
Rhesus D factor (RhD) negative women's experiences with pregnancy: An interpretive description.
CONCLUSION: RhD negative women want information and to be involved in the decision-making process in the prevention of RhD alloimmunization. Working with RhD negative women to develop decision-aids and/or other educational tools to aid in the decision-making process are warranted. PMID: 32035799 [PubMed - as supplied by publisher] (Source: Women Birth)
Source: Women Birth - February 5, 2020 Category: Midwifery Authors: Fyfe TM, Lavoie JG, Payne GW, Banner D Tags: Women Birth Source Type: research
Real-World Evaluation of Efficacy and Tolerability of Immune Globulin Subcutaneous 16.5% in the Treatment of Patients with Primary Immunodeficiency
Immune Globulin Subcutaneous (Human), 16.5% solution (IGSC 16.5%) is a new subcutaneous immunoglobulin for the treatment of primary immunodeficiencies (PID). Available from Octapharma as Cutaquig ® since May 2019, we report the first real-world data regarding use of IGSC 16.5%. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2020 Category: Allergy & Immunology Authors: Richard Herrscher, Jeffrey Langford, Samantha Kuten, Lucinda Van Anglen Source Type: research
Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI)
This trial assessed the safety and tolerability of IGSC-C 20% and intravenous immune globulin infusion (human),10% caprylate/chromatography purified (IGIV-C 10%) in participants with PI. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2020 Category: Allergy & Immunology Authors: H. James Wedner, John Sleasman, William Lumry, Iftikhar Hussain, James Harris, Elsa Mondou, Jiang Lin, Carrie Hames, Montse Querolt, Mark Stein Source Type: research
Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multicenter, phase 3 study
Immune globulin subcutaneous, human – klhw 20% solution (IGSC-C 20%) is a new treatment for patients with PI. The primary objective determined whether the pharmacokinetics (PK) of IGSC-C 20% is noninferior to intravenous (IV) immune globulin injection (human),10% caprylate/chromatography purified (IGIV-C 10%). (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2020 Category: Allergy & Immunology Authors: John Sleasman, William Lumry, Iftikhar Hussain, H. James Wedner, James Harris, Elsa Mondou, Jiang Lin, Carrie Hames, Montse Querolt, Mark Stein Source Type: research
Infusion Parameters of Patients Initiated on Ig20Gly in a Patient Program by Infusion Schedule
HelloCuvitru is a patient program that provides the first 4 infusions of Cuvitru ® (Immune Globulin Subcutaneous [Human], 20% Solution, Ig20Gly) at home and free-of-charge to eligible patients who have primary immunodeficiency diseases (PID). We assessed patient characteristics and infusion parameters by infusion schedules. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2020 Category: Allergy & Immunology Authors: Lisa Meckley, Yanyu Wu, Spiros Tzivelekis, Vivek Gandhi, Andre Gladiator Source Type: research
Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients With Immunodeficiencies Receiving Weekly Immune Globulin Subcutaneous [Human] 20% Solution (Ig20Gly)
Clinical trials in immunodeficiencies commonly characterize serum immunoglobulin G (IgG) pharmacokinetic (PK) profiles using serial serum IgG levels throughout immunoglobulin (IG) treatment, complicating the conduct of clinical trials as well as imposing burdens on patients. This retrospective analysis evaluated whether steady-state serum IgG trough level measurement alone is adequate for PK assessment. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2020 Category: Allergy & Immunology Authors: Zhaoyang Li, Barbara McCoy, Leman Yel Source Type: research
Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis
Purpose of review To review the clinical characteristics, radiological manifestations and treatment of myelin oligodendrocyte glycoprotein (MOG)-immunoglobulin G (IgG) optic neuritis. Recent findings Serum antibodies to MOG have recently been found to be a biomarker of MOG-IgG-associated disorder (MOGAD), a demyelinating disease distinct from both multiple sclerosis (MS) and aquaporin-4-IgG neuromyelitis optica spectrum disorder (AQP4-IgG-positive NMOSD). The phenotype of MOGAD is broad and includes optic neuritis, transverse myelitis, and acute demyelinating encephalomyelitis (ADEM). Optic neuritis is the most common...
Source: Current Opinion in Neurology - January 17, 2020 Category: Neurology Tags: NEURO-OPHTHALMOLOGY: Edited by Heather E. Moss Source Type: research
Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment
Semin Thromb Hemost DOI: 10.1055/s-0039-1700512Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder affecting approximately 1 in 20,000 people. Patients typically present with clinically benign mucocutaneous bleeding, but morbid internal bleeding can occur. Diagnosis remains clinical, possible only after ruling out other causes of thrombocytopenia through history and laboratory testing. Many adult patients do not require treatment. For those requiring intervention, initial treatment of adult ITP is with corticosteroids, intravenous immunoglobulin, or intravenous anti-RhD immune globulin. These agents are rapid-...
Source: Seminars in Thrombosis and Hemostasis - December 12, 2019 Category: Hematology Authors: Al-Samkari, Hanny Kuter, David J. Tags: Review Article Source Type: research
Survey of Impediments to Prevention of Mother-to-infant Transmission of Hepatitis B Virus by International Societies
Conclusions: Our study demonstrated multiple obstacles to achieving the goal of preventing MIT of HBV. Comprehensive public health programs to enhance vaccine coverage rate, supply HBV vaccine for out-born neonates, screening maternal HBV markers, treating highly viremic pregnant mothers are proposed to overcome these obstacles and achieve the goal of preventing MIT of HBV. (Source: Journal of Pediatric Gastroenterology and Nutrition)
Source: Journal of Pediatric Gastroenterology and Nutrition - November 21, 2019 Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
Towards optimal patient selection for bronchial thermoplasty treatment in severe asthma: results from the TASMA randomized trial
Background: Bronchial Thermoplasty (BT) is a treatment for severe uncontrolled asthma patients. Although studies have shown clinical improvement after BT, not all patients respond equally well. Identifying optimal candidates for BT treatment is needed.Aim: To identify patient characteristic differences between BT responders and non-responders.Methods: Patients from the multicenter TASMA trial were included in this analysis. Before BT, a set of clinical, functional, inflammatory and airway biopsy data were collected (Table 1). A positive BT response was defined as a minimal clinically important change of>0.5 on asthma co...
Source: European Respiratory Journal - November 21, 2019 Category: Respiratory Medicine Authors: Goorsenberg, A. W. M., DHooghe, J. N. S., Ten Hacken, N. H. T., Weersink, E. J. M., Bel, E. H., Shah, P. L., Annema, J. T., Bonta, P. I. Tags: Airway pharmacology and treatment Source Type: research
A Fatal Case of Severe Systemic Varicella Zoster Infection in a Patient with Chronic Use of Immunosuppressive Agents for Cutaneous Vasculitis
Publication date: Available online 9 November 2019Source: IDCasesAuthor(s): Lin Wei-Chen, Chang Ching, Ko Meng-Cheng, Lin Shu-MinAbstractAcute varicella zoster virus (VZV) infection is a common condition in children, which is considered a mild, self-limited disease with diffuse skin vesicular rash. However, disseminated VZV infection with multiple organ involvement can occur in immunocompromised patients with impaired T cell immunity including solid or hematopoietic stem cell transplant recipients, receiving immunosuppressive therapy, leukemia, lymphoma, and HIV infection. Prompt antiviral therapy is mandatory in those imm...
Source: IDCases - November 10, 2019 Category: Infectious Diseases Source Type: research
Expansion of the 1st WHO international standard for antiserum to respiratory syncytial virus to include neutralisation titres against RSV subtype B: An international collaborative study.
Abstract An International Standard to harmonise results from RSV subtype A neutralisation assays was generated and established by the World Health Organization in 2018. Here we report on a study to expand the use of that standard to include neutralisation assays using human sera against RSV subtype B and to test its ability to harmonise neutralisation titres from neutralisation assays including complement. The study included 11 laboratories from 6 countries. All participants used their own in-house virus neutralisation assay and their own virus stocks. The study samples comprised the current International Standard...
Source: Vaccine - November 7, 2019 Category: Allergy & Immunology Authors: McDonald JU, Rigsby P, Atkinson E, Engelhardt OG, Study Participants Tags: Vaccine Source Type: research
[Autoimmune hemolytic anemia and immune thrombocytopenia associated with Hodgkin disease: Retrospective monocentric study].
CONCLUSION: In our series, the predominance of males, a higher frequency of immune thrombocytopenia than autoimmune hemolytic anemia, the resistance to usual treatments and the efficacy of specific chemotherapy were consistent with the literature. Unexpectedly, patients were young and with nodular sclerosis morphology (vs. mixed cellularity) in 3 of 4 cases. PMID: 31668883 [PubMed - as supplied by publisher] (Source: Revue de Medecine Interne)
Source: Revue de Medecine Interne - November 2, 2019 Category: Internal Medicine Tags: Rev Med Interne Source Type: research
A Study of Tolerability, Satisfaction, and Cost Reduction Using a 10% Immunoglobulin Product at Higher Administration Rates
Gammaplex 10% (immune globulin intravenous [human], Bio Products Laboratory, Ltd) can be administered with a 15-minute rate-escalation protocol. This analysis examined safety, patient satisfaction, and cost savings in 49 patients administered Gammaplex 10% via rapid infusion over 11 months. Fourteen patients reported 38 adverse reactions, 37 of which were deemed minor/moderate. Patient satisfaction was very good/outstanding. Infusions were estimated to be 2.4 hours shorter than previously administered intravenous immunoglobulin infusions, saving $151.61 per visit in nursing costs. Rapid infusion of Gammaplex 10% was found ...
Source: Journal of Infusion Nursing - November 1, 2019 Category: Nursing Tags: Features Source Type: research
M271 ctla-4 haploinsufficiency: the case for whole exome sequencing in common variable immune deficiency (cvid)
We describe a case in which whole exome sequencing (WES) in a patient with CVID and associated lung disease revealed a new option for therapy. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2019 Category: Allergy & Immunology Authors: S. Jiang, M. Tsai, M. Butte Source Type: research
P252 a device for facilitated subcutaneous immunoglobulin using patient-centric design and modular innovation principles
Immune Globulin Infusion (IGI) 10% (Human) facilitated with Recombinant Human Hyaluronidase (rHuPH20; fSCIG) is approved for treatment of primary and secondary immunodeficiency diseases (PID and SID) in Europe, and for adult patients with PID in the United States. For fSCIG administration, rHuPH20 is infused before immunoglobulin administration. rHuPH20 and immunoglobulin G (IgG) are co-packaged in dual-vial units (DVUs) to ensure correct ratios of the drugs are administered. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2019 Category: Allergy & Immunology Authors: S. Ariagno, S. Holzner, M. Gibson, S. Jones, T. Amsler, K. Duff Source Type: research
Effect of Different Selenium Sources on Growth Performance, Tissue Selenium Content, Meat Quality, and Selenoprotein Gene Expression in Finishing Pigs.
This study compared the effects of sodium selenite (SeNa), MeSeCys, and selenomethionine (SeMet) on immune function, tissue Se concentration, meat quality, and selenoprotein gene expression in pigs. A total of 72 finishing pigs were divided into four groups, which received a basal diet (BD, 0.1 mg Se/kg) without Se supplementation or one supplemented with SeNa, MeSeCys, or SeMet at a concentration of 0.25 mg Se/kg. Organic Se supplementation significantly increased the immune globulin A (IgA), IgG, and IgM serum levels compared with BD and SeNa groups (P
Source: Biological Trace Element Research - October 29, 2019 Category: Biology Authors: Zhang K, Zhao Q, Zhan T, Han Y, Tang C, Zhang J Tags: Biol Trace Elem Res Source Type: research
Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab.
CONCLUSION: This case highlights both a novel and successful approach to managing refractory transfusion-induced hyperhemolysis with tocilizumab and provides further evidence supporting the role for macrophage activation in the destruction of RBCs in antibody-negative HHS. We propose that tocilizumab is an effective and rapid salvage therapy for refractory HHS. PMID: 31642065 [PubMed - as supplied by publisher] (Source: Transfusion)
Source: Transfusion - October 23, 2019 Category: Hematology Authors: Lee LE, Beeler BW, Graham BC, Cap AP, Win N, Chen F Tags: Transfusion Source Type: research
Kawasaki disease triggered by EBV virus in a child with Familial Mediterranean Fever
ConclusionsMutations of MEFV can contribute to increase inflammatory expression in other diseases, as Kawasaki disease. (Source: Italian Journal of Pediatrics)
Source: Italian Journal of Pediatrics - October 18, 2019 Category: Pediatrics Source Type: research
Immune globulin subcutaneous, human – klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - October 17, 2019 Category: Allergy & Immunology Authors: John W Sleasman William R Lumry Iftikhar Hussain H James Wedner James B Harris Kecia L Courtney Elsa Mondou Jiang Lin Mark R Stein Source Type: research
Optimization of intravenous immune globulin use at a comprehensive cancer center.
The objective of this study was to quantify the waste reduction potential generated through the use of alternative IVIG dosing weights. METHODS: We performed a retrospective analysis of all IVIG doses administered from January 2011 to 2016 to adults (≥18 years). TBW and height at the time of administration were used to calculate prescribed dose (g/kg), ideal body weight (IBW), and adjusted body weight (AdjBW). Three dosing methods were analyzed, as follows: use of AdjBW if TBW is>120% IBW (method 1), AdjBW for all doses (method 2), and IBW for all doses (method 3). Outcomes included potential IVIG use averted, d...
Source: American Journal of Health-System Pharmacy : AJHP - October 17, 2019 Category: Drugs & Pharmacology Authors: Figgins BS, Aitken SL, Whited LK Tags: Am J Health Syst Pharm Source Type: research
Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.
CONCLUSIONS: This is the first report demonstrating ACPAs in OSW of DED patients and their contribution to ocular surface disease. The first-in-human clinical trial suggests that pooled immune globulin-eye drops are a potential new class of biologic therapies for Dry Eye patients. PMID: 31606460 [PubMed - as supplied by publisher] (Source: The Ocular Surface)
Source: The Ocular Surface - October 10, 2019 Category: Opthalmology Authors: Kwon J, Surenkhuu B, Raju I, Atassi N, Mun J, Chen YF, Sarwar MA, Rosenblatt M, Pradeep A, An S, Dhall N, Mun C, Jain S Tags: Ocul Surf Source Type: research
Outcomes Associated With Standardized Ideal Body Weight Dosing of Intravenous Immune Globulin in Hospitalized Patients: A Multicenter Study.
Conclusion and Relevance: The implementation of a standardized IBW IVIG dosing strategy was not associated with a statistically significant increase in 30-day hospital readmission or LOS but was associated with significantly fewer grams per dose given. Application of these data may aid in decreasing institutional drug spend without affecting patient outcomes. However, the study was underpowered, and further investigation is necessary to validate these findings. PMID: 31578070 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 3, 2019 Category: Drugs & Pharmacology Authors: Grindeland JW, Grindeland CJ, Moen C, Leedahl ND, Leedahl DD Tags: Ann Pharmacother Source Type: research
Kawasaki Disease: Beyond IVIG and Aspirin.
This article reviews the clinical characteristics of KD, laboratory assessment, echocardiogram findings, and recommended initial medical therapy. Complications of KD are discussed, including KD refractory to IVIG, the presence of shock or macrophage activation syndrome (MAS), and short/long-term cardiac sequelae. The medical management of these complications is reviewed. Although improved treatment of KD has resulted in a decrease of coronary artery vasculitis over the past 3 decades, KD remains the most common cause of acquired heart disease in children. [Pediatr Ann. 2019;48(10):e400-e405.]. PMID: 31609999 [PubMed -...
Source: Pediatric Annals - October 1, 2019 Category: Pediatrics Authors: Moussa T, Wagner-Weiner L Tags: Pediatr Ann Source Type: research
Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2/3 trial
. (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - September 24, 2019 Category: Allergy & Immunology Authors: Mark A. Matson Eran Schenker Michal Stein Vladislava Zamfirova Huy-Binh Nguyen Garrett E. Bergman Source Type: research
Perinatal outcomes of intrauterine transfusion for foetal anaemia due to red blood cell alloimmunisation.
Authors: Şavkli AÖ, Çetin BA, Acar Z, Özköse Z, Behram M, Çaypinar SS, Tayyar A, Yüksel MA Abstract The aim of this study was to evaluate the maternal and neonatal outcomes of patients who underwent intrauterine transfusion (IUT) for foetal anaemia due to red blood cell alloimmunisation and to determine the factors that affected the outcomes. All pregnancies that were treated with IUT due to Rh immunisation between January 2015 and June 2018 in the Kanuni Sultan Süleyman Training and Research Hospital, Department of Obstetrics and Gynaecology, were evaluated retrospectively. ...
Source: Journal of Obstetrics and Gynaecology - August 31, 2019 Category: OBGYN Tags: J Obstet Gynaecol Source Type: research
Medication stewardship using computerized clinical decision support: A case study on intravenous immunoglobulins
AbstractBackgroundHealthcare delivery organizations face increasing pressure to manage the use of medications in terms of safety, waste reduction, and cost containment.ObjectiveTo describe a computerized provider order entry (CPOE) system intervention to optimize use of a commonly ordered, high ‐cost therapeutic: intravenous immune globulin (IVIG).DesignDescription of IVIG order configuration, medication use patterns, and subsequent order set configuration development in a CPOE system.MeasurementsIVIG orders were extracted from the CPOE system before and after the implementation of a specialty orderset to determine the i...
Source: Pharmacology Research and Perspectives - August 29, 2019 Category: Drugs & Pharmacology Authors: Demetra Tsapepas, Caroline Der-Nigoghossian, Khilna Patel, Karen Berger, David K Vawdrey, Hojjat Salmasian Tags: ORIGINAL ARTICLE Source Type: research
Plasma galectin ‐3 levels do not differ in systemic lupus erythematosus patients
ConclusionsIn summary, plasma galectin ‐3 level was not significantly different between SLE patients and controls (P = .982). Further studies are needed to elucidate the role of galectin‐3 in SLE. (Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - August 11, 2019 Category: Rheumatology Authors: Chan ‐Na Zhao, Yan‐Mei Mao, Li‐Na Liu, Qian Wu, Yi‐Lin Dan, Hai‐Feng Pan Tags: ORIGINAL ARTICLE Source Type: research
Adherence to guideline recommendations for human rabies immune globulin patient selection, dosing, timing, and anatomical site of administration in rabies postexposure prophylaxis
. (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - August 1, 2019 Category: Allergy & Immunology Authors: Grace S. Hwang Elsie Rizk Lan N. Bui Tomona Iso Emily I. Sartain Anh Thu Tran Joshua T. Swan Source Type: research
Immune Globulin Subcutaneous (Human) 20% (Hizentra ® ): A Review in Chronic Inflammatory Demyelinating Polyneuropathy
AbstractIntravenous immunoglobulin (IVIg) is well-established in the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Immune globulin subcutaneous (human) 20% liquid (Hizentra®; referred to as IgPro20 hereafter) has recently been approved in a number of countries, including the USA and those of the EU, as maintenance therapy in patients with CIDP. In the pivotal phase III PATH trial in adults with CIDP who were first stabilized on IVIg therapy, maintenance therapy with IgPro20 for 24 weeks significantly reduced CIDP relapse or study withdrawal rates versus placebo. Efficacy was...
Source: CNS Drugs - July 25, 2019 Category: Neurology Source Type: research
Pre-operative Therapeutic Plasma Exchange and Intravenous Immune Globulin for the treatment of Heparin Induced Thrombocytopenia in a lung transplant recipient
Lung transplantation surgery often relies on the use of intraoperative extracorporeal membrane oxygenation (ECMO) and necessitates the need for high dose anticoagulation. Heparin induced thrombocytopenia complicates intraoperative anticoagulation management during lung transplant surgery requiring ECMO. Though other anticoagulants such as argatroban and bivalrudin are utilized for the treatment of Heparin Induced Thrombocytopenia (HIT), the lack of reversal agents makes it difficult to use these agents intraoperatively in cases with high bleeding risk. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - July 22, 2019 Category: Hematology Authors: Molly W. Mandernach, Sravanthi Nandavaram, Bilal Salame, Tiago Machuca, Andres Pelaez Source Type: research